Afatinib is an irreversible ErbB family blocker and a second-generation EGFR-TKI, and its efficacy as first-line treatment for patients with advanced EGFR mutation-positive lung adenocarcinoma has subsequently been proven [8–10]. This evidence concerns the gene EGFR and lung adenocarcinoma.